FDA Inspection 1179624 — Loxo Oncology, Inc.
The FDA completed an inspection of Loxo Oncology, Inc. on Sep 9, 2022 in South San Francisco, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 9, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- South San Francisco, CA (United States)
Additional Details
Sponsor, Contract Research Organization